Scohia Pharma

China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced an expanded global strategic partnership for the GLP-1R and GIPR dual agonist SCO-094 and its derivatives. This collaboration aims to accelerate the development and commercialization of SCO-094, a promising treatment for type 2 diabetes, obesity,…